Patents Issued in July 30, 2019
  • Patent number: 10363240
    Abstract: The present invention is directed to a composition for treating alopecia containing minoxidil, cyclosporine A and a compound that binds FK506 binding protein 4 suitable for administration to humans. The present invention is further directed to treating alopecia in humans by administering a composition of the invention.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 30, 2019
    Assignee: DAVID WEINSTEIN CONSULTING, INC.
    Inventor: David Weinstein
  • Patent number: 10363241
    Abstract: The present invention provides intermediates for methods for synthesizing compounds of Formula (I) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: July 30, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Patent number: 10363243
    Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: July 30, 2019
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple
  • Patent number: 10363244
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 30, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Patent number: 10363245
    Abstract: Provided herein are methods for repairing central nervous system, particularly brain, lesions in a subject comprising orally administering a carbonic anhydrase inhibitor.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 30, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jerry S. Wolinsky, John A. Lincoln, Leorah A. Freeman, Ponnada A. Narayana
  • Patent number: 10363246
    Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 30, 2019
    Assignee: Ovid Therapeutics Inc.
    Inventor: Matthew During
  • Patent number: 10363247
    Abstract: The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: July 30, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis
  • Patent number: 10363248
    Abstract: The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Timothy McAfoos
  • Patent number: 10363249
    Abstract: Compounds that are fatty acid synthesis modulators are provided. The compounds may be used in pharmaceutical compositions to treat taxane-resistant cancers. Methods are provided for treating taxane-resistant cancer in a subject. Methods are also provided for increasing the sensitivity of a cancer cell to taxanes (i.e., paclitaxel, Nab-paclitaxel docetaxel, and/or cabazitaxel) treatment.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: July 30, 2019
    Assignee: 3-V Biosciences, Inc.
    Inventor: Timothy Sean Heuer
  • Patent number: 10363250
    Abstract: Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating stroll diseases are also described.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 30, 2019
    Assignees: Endocyte, Inc., Purdue Research Foundation
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Philip Stewart Low
  • Patent number: 10363251
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat a variety of disorders.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 30, 2019
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Patent number: 10363252
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 30, 2019
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Patent number: 10363253
    Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 30, 2019
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André E. Roymans, Anil Koul
  • Patent number: 10363254
    Abstract: Methods for treating or prophylaxis of a Cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of Cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: July 30, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher D. Huston, Kovi Bessoff, Rajiv Satish Jumani
  • Patent number: 10363255
    Abstract: The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 30, 2019
    Assignee: FORSIGHT VISION4, INC.
    Inventors: Judit Horvath, Irina Astafieva, Signe Erickson, Kathleen Cogan Farinas
  • Patent number: 10363256
    Abstract: Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 30, 2019
    Assignees: University of Washington, The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone
    Inventors: Thomas A. Reh, Paul Nakamura, Sheng Ding
  • Patent number: 10363257
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 30, 2019
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Roland Young
  • Patent number: 10363258
    Abstract: Provided herein are prostaglandin F2? analog compositions and methods for treating migraines.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 30, 2019
    Assignee: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Patent number: 10363259
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: July 30, 2019
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Nageswara R. Palepu
  • Patent number: 10363260
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 30, 2019
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson
  • Patent number: 10363261
    Abstract: Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Florian Muller, David S. Maxwell, William G. Bornmann, Yu-Hsi Lin, Basvoju A. Bhanu Prasad, Zhenghong Peng, Duoli Sun, Nikunj Satani, M. Emilia Di Francesco, Ronald A. Depinho, Barbara Czako, Federica Pisaneschi
  • Patent number: 10363262
    Abstract: The present invention relates to a composition for wound healing or skin regeneration comprising gypenoside 75 (gypenoside LXXV) as an active ingredient.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: July 30, 2019
    Assignee: INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Sun-Chang Kim, Sungjoo Park, Eun Su Ko
  • Patent number: 10363263
    Abstract: The invention generally relates to anti-aging compositions and methods for using the anti-aging compositions. In one aspect, the invention provides a method for preventing cellular aging in a cell of a subject, the method comprising the step of providing to the cell an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizie triterpenoid compound or a pharmaceutically acceptable salt thereof, thereby preventing the cell from aging. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 30, 2019
    Assignee: Prescient Pharma, LLC
    Inventors: Pavel Idelevich, Anna Idelevich
  • Patent number: 10363264
    Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: July 30, 2019
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Feyruz Rassool, Stephen Baylin, Carine Robert
  • Patent number: 10363265
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: July 30, 2019
    Assignees: Idenix Pharmaceuticals LLC, Universita Degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo La Colla
  • Patent number: 10363266
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 30, 2019
    Assignee: NeuroVision Pharma GmbH
    Inventors: Markus Hossbach, Monika Krampert, Hans-Lothar Arth
  • Patent number: 10363267
    Abstract: It is an object of the present invention to provide a nutritional composition for preventing diarrhea enabling ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form. A nutritional composition that is prepared by selecting a pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85% among pectins, and mixing the selected pectin with lipid, carbohydrate and protein, enables ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 30, 2019
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Kazuo Hino, Naoyuki Endo, Sho Miyatake
  • Patent number: 10363268
    Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 30, 2019
    Assignee: TRICIDA, INC.
    Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
  • Patent number: 10363269
    Abstract: Provided are polynucleotides containing a modified PRE having a variant X gene that includes one or more stop codons not present in an unmodified, such as wild-type, hepatitis X gene. Also provided are polynucleotides containing a modified PRE having a variant X gene that includes one or more degradation sequences not present in an unmodified, such as wild-type, hepatitis X gene. The modified PRE can be operably linked to a nucleic acid encoding a recombinant protein. Also provided are expression cassettes, viral vectors and cells containing the polynucleotides, and compositions and methods of use thereof.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: July 30, 2019
    Assignee: Juno Therapeutics, Inc.
    Inventor: Semih U. Tareen
  • Patent number: 10363270
    Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 30, 2019
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 10363271
    Abstract: A method of making a composition for influencing biological growth includes obtaining a sample comprising human umbilical cord blood and having a first volume VUC, combining the sample with a quantity of PrepaCyte-CB or the equivalent having a volume VPC, wherein the ratio VUC/VPC is between about 0.60 and about 1.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 30, 2019
    Assignee: SMART Surgical, Inc.
    Inventors: Christopher D. Jones, Nathan Quintanar
  • Patent number: 10363272
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 30, 2019
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10363273
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 30, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10363274
    Abstract: The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 30, 2019
    Assignee: INREGEN
    Inventors: Joydeep Basu, Kelly Guthrie, Dominic Justewicz, Teresa Burnette, Andrew Bruce, Russell W. Kelley, John W. Ludlow
  • Patent number: 10363275
    Abstract: The present invention relates to a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and/or mesenchymal stem/progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem/progenitor cells into epithelial and/or mesenchymal cells.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: July 30, 2019
    Assignee: CellResearch Corporation Pte Ltd
    Inventors: Toan-Thang Phan, Ivor Jiun Lim
  • Patent number: 10363276
    Abstract: Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 30, 2019
    Assignees: The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Martin Leon Yarmush, Biju Parekkadan
  • Patent number: 10363277
    Abstract: Rhinoceros horn analogs and methods of synthesis thereof. Compounds with medicinal effects can be incorporated into the analogs. Genetic fingerprints can also be incorporated into the analogs. The analogs can be formulated into compositions.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: July 30, 2019
    Assignee: Pembient, Inc.
    Inventors: George A. Bonaci, Matthew Markus
  • Patent number: 10363278
    Abstract: A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at ?20° C. for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 30, 2019
    Assignee: Amnio Technology LLC
    Inventors: Christian Beaudry, Terrell Suddarth, Bruce Werber
  • Patent number: 10363279
    Abstract: An embodiment is a method of preventing, mitigating or treating neurological conditions and diseases that includes administering an effective amount of a medicament comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to a human to prevent, mitigate or treat neurological conditions and diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 30, 2019
    Assignee: NuBiome, Inc.
    Inventor: Brian C. Lue
  • Patent number: 10363280
    Abstract: A nutraceutical food product includes a solid matrix and a liquid combined into a gel. The nutraceutical food product may include an immune modulator, such as transfer factor and/or a nanofraction immune modulator. A fruit component may be included in the nutraceutical food product. The fruit component may include at least one oligoproanthocyanidin-containing fruit, such as açai.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 30, 2019
    Assignee: 4Life Patents, LLC
    Inventors: Brent M. Vaughan, Calvin W. MacCausland, David A. Lisonbee
  • Patent number: 10363281
    Abstract: A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 30, 2019
    Assignee: TissueGen, Inc.
    Inventors: Kevin D. Nelson, Brent B. Crow, Nickolas B. Griffin, Jennifer Seifert, Paul R. Sood, Alpeshkumar P. Patel, Paul A. Hubbard
  • Patent number: 10363282
    Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2019
    Assignees: Board of Regents of The University of Nebraska, San Diego State University Research Foundation
    Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
  • Patent number: 10363284
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa3, Xaa6, Xaa8, Xaa13, Xaa14 and Xaa15 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: July 30, 2019
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Alexander Lederer, Johann Zimmermann, Christian Oefner
  • Patent number: 10363285
    Abstract: Disclosed herein are methods and compositions for providing mixtures of FGF2 isoforms that are biologically active. The biological activities include, but are not limited to, stimulation of proliferation of neural precursor cells, stimulation of proliferation of endothelial cells, stimulation of development of neural precursor cells, and stimulation of development of astrocytes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 30, 2019
    Assignee: SanBio, Inc.
    Inventors: Irina Aizman, Damien Bates
  • Patent number: 10363286
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 30, 2019
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • Patent number: 10363287
    Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 30, 2019
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
  • Patent number: 10363288
    Abstract: Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive T cells into Foxp3+ regulatory T cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: July 30, 2019
    Assignees: National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: Aaron Michels, John Kappler, Peter A. Gottlieb
  • Patent number: 10363289
    Abstract: The invention is directed toward mutant, non-wild-type organophosphorus acid anhydrolase enzymes having three site mutations, methods of production, and methods of use to effectively degrade toxic organophosphorus compounds, most preferably GP (2, 2?-dimethylcyclopentyl methylphosphonofluoridate).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 30, 2019
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Steven P. Harvey, Mark A Guelta, Leslie R McMahon
  • Patent number: 10363290
    Abstract: The present invention provides recombinant butyrylcholinesterase fusion proteins, including Fc fusion proteins and multi-armed high MW polymers containing hydrophilic groups conjugated to the fusion proteins, and methods of preparing such polymers.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: July 30, 2019
    Assignee: KODIAK SCIENCES INC.
    Inventors: D. Victor Perlroth, Stephen A. Charles, Wayne To, Xiaojian Huang, Martin Linsell, Didier Benoit
  • Patent number: 10363291
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: July 30, 2019
    Assignee: Genzyme Corporation
    Inventor: Yunxiang Zhu